Ex-Purdue CEO stands to earn a huge windfall in Novartis' buyout of the Medicines Co
Mark Timney, the ex-Purdue Pharma CEO named in dozens of lawsuits against the OxyContin maker, stands to earn over $85 million in Novartis’s $9.7 billion buyout of the Medicines Company.
Timney joined the Medicines Company as CEO in December, after four years helming the company broadly considered to be at the heart of the opioid abuse crisis. SEC filings from the time of his hire show he agreed to purchase $500,000 worth of stock at the time and was also granted one million performance and time-vested stock options.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.